Trial Outcomes & Findings for Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19 (NCT NCT04912895)
NCT ID: NCT04912895
Last Updated: 2023-09-07
Results Overview
The number of correct identification of participants with SARS-CoV-2 infection (true positives) detected by RNA in cough-generated droplets captured with the PneumoniaCheck.
COMPLETED
NA
69 participants
Up to Hour 24
2023-09-07
Participant Flow
Participants were recruited from the Emory Children's Center, Emory University Hospital Midtown, Emory University Hospital, and the Wesley Woods Center in Atlanta, Georgia, USA. Participant enrollment began April 14, 2022 and all follow-up assessments were completed by August 5, 2022.
The study initially planned to recruit participants with non-coronavirus disease 2019 (COVID-19) respiratory illness, however, resources did not permit including this study arm.
Participant milestones
| Measure |
PneumoniaCheck Among SARS-CoV-2 Positive Participants
Participants who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the polymerase chain reaction (PCR) test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Non-COVID-19 Acute Respiratory IllnessParticipants
Participants who have an acute respiratory illness other than SARS-CoV-2 infection use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|---|
|
Overall Study
STARTED
|
51
|
0
|
18
|
|
Overall Study
COMPLETED
|
49
|
0
|
18
|
|
Overall Study
NOT COMPLETED
|
2
|
0
|
0
|
Reasons for withdrawal
| Measure |
PneumoniaCheck Among SARS-CoV-2 Positive Participants
Participants who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the polymerase chain reaction (PCR) test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Non-COVID-19 Acute Respiratory IllnessParticipants
Participants who have an acute respiratory illness other than SARS-CoV-2 infection use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|---|
|
Overall Study
Unable to provide specimen
|
2
|
0
|
0
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=51 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
Total
n=69 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=51 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=69 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
51 Participants
n=51 Participants
|
18 Participants
n=18 Participants
|
69 Participants
n=69 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=51 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=69 Participants
|
|
Sex/Gender, Customized
Female
|
27 Participants
n=51 Participants
|
0 Participants
n=18 Participants
|
27 Participants
n=69 Participants
|
|
Sex/Gender, Customized
Male
|
21 Participants
n=51 Participants
|
0 Participants
n=18 Participants
|
21 Participants
n=69 Participants
|
|
Sex/Gender, Customized
Not collected
|
3 Participants
n=51 Participants
|
18 Participants
n=18 Participants
|
21 Participants
n=69 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
United States
|
51 Participants
n=51 Participants
|
18 Participants
n=18 Participants
|
69 Participants
n=69 Participants
|
PRIMARY outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The number of correct identification of participants with SARS-CoV-2 infection (true positives) detected by RNA in cough-generated droplets captured with the PneumoniaCheck.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Sensitivity of Detecting SARS-CoV-2 RNA
|
31 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The number of correct identification of participants without SARS-CoV-2 infection (true negatives) detected by RNA in cough-generated droplets captured with the PneumoniaCheck.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Specificity of Detecting SARS-CoV-2 RNA
|
10 Participants
|
18 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IFN gamma, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IFN Gamma Detected
|
0.201 picograms per milliliter (pg/mL)
Interval 0.029 to 0.342
|
0.229 picograms per milliliter (pg/mL)
Interval 0.003 to 2.222
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-1 beta, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of Interleukin (IL)-1 Beta Detected
|
0.140 pg/mL
Interval 0.052 to 0.566
|
0.131 pg/mL
Interval 0.076 to 64.522
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-1 beta, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-2 Detected
|
0.157 pg/mL
Interval 0.071 to 0.271
|
0.219 pg/mL
Interval 0.117 to 1.355
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-4, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-4 Detected
|
0.009 pg/mL
Interval 0.004 to 0.041
|
0.009 pg/mL
Interval 0.003 to 0.104
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-6, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-6 Detected
|
0.081 pg/mL
Interval 0.02 to 0.531
|
0.076 pg/mL
Interval 0.001 to 3.763
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-8, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-8 Detected
|
0.132 pg/mL
Interval 0.037 to 9.984
|
0.095 pg/mL
Interval 0.019 to 639.432
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-10, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-10 Detected
|
0.028 pg/mL
Interval 0.015 to 0.113
|
0.031 pg/mL
Interval 0.019 to 0.634
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-12p70, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-12p70 Detected
|
0.088 pg/mL
Interval 0.04 to 0.13
|
0.082 pg/mL
Interval 0.033 to 0.543
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-13, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of IL-13 Detected
|
0.618 pg/mL
Interval 0.364 to 0.708
|
0.420 pg/mL
Interval 0.141 to 7.549
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24Population: This analysis includes participants who successfully provided a cough sample using the PneumoniaCheck.
The researchers detected biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including TNF alpha, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
| Measure |
PneumoniaCheck Among SARSCoV-2 Positive Participants
n=49 Participants
Participants who test positive for SARS-CoV-2 with the PCR test use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
PneumoniaCheck Among Healthy Controls
n=18 Participants
Participants without any acute respiratory illness use the PneumoniaCheck device to collect material from the lung from coughs. Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
|
|---|---|---|
|
Amount of Tumour Necrosis Factor (TNF) Alpha Detected
|
0.026 pg/mL
Interval 0.004 to 0.086
|
0.017 pg/mL
Interval 0.001 to 2.211
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-1 alpha, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IFN alpha, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including GM-CSF, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory cytokines, including IL-17A, in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory chemokines, including IP-10, also known as C-X-C motif chemokine ligand 10 (CXCL10), in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory chemokines, including MIP-1 alpha, also known as C-C motif chemokine ligand 3 (CCL3), in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory chemokines, including MCP-1, also known as C-C motif chemokine ligand 2 (CCL2), in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting surfactant A chemokines in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Hour 24The researchers will detect biomarkers of inflammation in coughed specimens from patient with COVID-19 hypothesizing that biomarkers of inflammation from the lung will indicate disease activity, informing pathogenesis of COVID-19 disease. The value of detecting inflammatory chemokines, including MIP-1 beta, also known as C-C motif chemokine ligand 4 (CCL4), in cough-generated droplets with PneumoniaCheck from COVID-19 patients will be evaluated.
Outcome measures
Outcome data not reported
Adverse Events
PneumoniaCheck Among SARSCoV-2 Positive Participants
PneumoniaCheck Among Healthy Controls
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place